Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.
Trotta MP, Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, Vullo V, Soscia F, Chiodera A, Ladisa N, Abeli C, Cauda R, Buonuomi AR, Antinori A, d'Arminio Monforte A; ICONA Foundation Study. Trotta MP, et al. Among authors: ladisa n. Clin Infect Dis. 2010 Aug 15;51(4):456-64. doi: 10.1086/655151. Clin Infect Dis. 2010. PMID: 20597690
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, et al. Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862. Clin Infect Dis. 2008. PMID: 18461712 Free PMC article.
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
Antiretroviral Therapy Cohort Collaboration (ART-CC); Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Antiretroviral Therapy Cohort Collaboration (ART-CC), et al. Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468. Clin Infect Dis. 2009. PMID: 19275498 Free PMC article.
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. Torti C, et al. BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23. BMC Infect Dis. 2011. PMID: 21266068 Free PMC article. Clinical Trial.
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.
Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, De Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, De Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE; MAGNIFICENT Consortium; INSIGHT; Swiss HIV Cohort Study. Rotger M, et al. Clin Infect Dis. 2013 Jul;57(1):112-21. doi: 10.1093/cid/cit196. Epub 2013 Mar 26. Clin Infect Dis. 2013. PMID: 23532479 Free PMC article.
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study.
Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Icona Foundation Study Group. Marchetti G, et al. BMC Infect Dis. 2014 Feb 12;14:79. doi: 10.1186/1471-2334-14-79. BMC Infect Dis. 2014. PMID: 24520976 Free PMC article.
Treatment-related factors and highly active antiretroviral therapy adherence.
Trotta MP, Ammassari A, Melzi S, Zaccarelli M, Ladisa N, Sighinolfi L, Mura MS, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Trotta MP, et al. Among authors: ladisa n. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S128-31. doi: 10.1097/00126334-200212153-00008. J Acquir Immune Defic Syndr. 2002. PMID: 12562035 Review.
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. Torti C, et al. Among authors: ladisa n. Clin Infect Dis. 2005 Jun 15;40(12):1828-36. doi: 10.1086/429917. Epub 2005 May 12. Clin Infect Dis. 2005. PMID: 15909273 Clinical Trial.
114 results